

Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs despite limited but durable responses.
You can purchase shares of Janux Therapeutics (NASDAQ:JANX) through any online brokerage.
Other companies in Janux Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Janux Therapeutics has a consensus price target of $47.75.
The stock price for Janux Therapeutics (NASDAQ: JANX) is $17.3 last updated November 6, 2026 at 1:44 PM EST.
There are no upcoming dividends for Janux Therapeutics.
Janux Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Janux Therapeutics.
Janux Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell...